尽管目前已经有了新的药物疗法，但囊性纤维化（cystic fibrosis）经常会导致永久性的肺部损伤，近日，一篇发表在国际杂志 Science Translational Medicine 上题为 “Perinatal dysfunction of ...

Hundreds of Lowcountry moms danced the night away all in support of research to support a treatment for a genetic disorder.

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...

The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...